Classification & Risk Stratification Prediction

circle-info

Classification & Risk Stratification Prediction is available for cases created using Connected Insights v5.1+.

Overview

If the case disease is Acute Myeloid Leukemia or a subtype, Classification & Risk Stratification Prediction is provided on the Overview Tab.

APL with PML::RARA fusion prediction with decision tree

Classification and risk stratification predictions are based on WHO 2022arrow-up-right and ELN 2022arrow-up-right acute myeloid leukemia guidelines, respectively, focusing on Acute myeloid leukemia with defining genetic abnormalities.

Select a box to review how the evaluation was performed. For more information, refer to Decision Trees below.

Reporting

The report interpretation summary can be generated from the prediction results by clicking Report.

Generated interpretation summary text

Decision Trees


APL with PML::RARA fusion

Classification

If the above is met, the classification is predicted to be APL with PML::RARA fusion.

Risk Stratification

If the above is met, the risk stratification is predicted to be Adverse. If not, then Intermediate.


AML with RUNX1::RUNX1T1 fusion

Classification

circle-info

The guideline specifies an outdated band 8q22 for RUNX1T1. It is now 8q21.3.

If the above is met, the classification is predicted to be AML with RUNX1::RUNX1T1 fusion.

Risk Stratification

If the above is met, the risk stratification is predicted to be Adverse. If not, then Favorable.


AML with CBFB::MYH11 fusion

Classification

If the above is met, the classification is predicted to be AML with CBFB::MYH11 fusion.

Risk Stratification

If the above is met, the risk stratification is predicted to be Adverse. If not, then Favorable.


AML with DEK::NUP214 fusion

Classification

If the above is met, the classification is predicted to be AML with DEK::NUP214 fusion.

Risk Stratification

Adverse


AML with RBM15::MRTFA fusion

Classification

If the above is met, the classification is predicted to be AML with RBM15::MRTFA fusion.

Risk Stratification

If the above is met, the risk stratification is predicted to be Adverse. If not, then Intermediate.


AML with BCR::ABL1 fusion

Classification

If the above is met, the classification is predicted to be AML with BCR::ABL1 fusion.

Risk Stratification

Adverse


AML with KMT2A rearrangement

Classification

If the above is met, the classification is predicted to be AML with KMT2A rearrangement.

Risk Stratification

If the above is met, the risk stratification is predicted to be Adverse. If not, then continue below.

  • Any of the following:

If the above is met, the risk stratification is predicted to be Intermediate. If not, then Adverse.


AML with MECOM rearrangement

Classification

If the above is met, the classification is predicted to be AML with MECOM rearragement.

Risk Stratification

Adverse


AML with NUP98 rearrangement

Classification

If the above is met, the classification is predicted to be AML with NUP98 rearrangement.

Risk Stratification

If the above is met, the risk stratification is predicted to be Adverse. If not, then Intermediate.


AML with NPM1 mutation

Classification

If the above is met, the classification is predicted to be AML with NPM1 mutation.

Risk Stratification

If the above is met, the risk stratification is predicted to be Adverse. If not, then continue below.

  • Detection of FLT3 internal tandem duplication with ≥ 2 allele depth or split reads and paired reads in the Variants Tab

If the above is met, the risk stratification is predicted to be Intermediate. If not, then Favorable.


AML with CEBPA mutation

Classification

circle-exclamation

If the above is met, the classification is predicted to be AML with CEBPA mutation.

Risk Stratification

If the above is met, the risk stratification is predicted to be Adverse. If not, then continue below.

If the above is met, the risk stratification is predicted to be Favorable. If not, then Intermediate.


AML with other defined genetic alterations

Classification

If the above is met, the classification is predicted to be AML with other defined genetic alterations.

Risk Stratification

If the above is met, the risk stratification is predicted to be Adverse. If not, then continue below.

If the above is met, the risk stratification is predicted to be Adverse. If not, then Intermediate.


Classification

If the above is met, the classification is predicted to be AML, myelodysplasia-related.

Risk Stratification

Any of the following:

If the above is met, the risk stratification is predicted to be Adverse. If not, then Intermediate.


Definitions

Complex Karyotype

According to WHO/ISCN: ≥ 3 abnormalities, where abnormalities are counted as follows:

  • Only clonal abnormalities are counted; abnormalities present in only 1 metaphase are ignored.

  • Numerical gains and losses, simple and complex balanced translocations, unbalanced aberrations involving one chromosome, as well as multiplication of a complete chromosome set are counted as one abnormality.

  • Unbalanced aberrations involving two or more chromosomes, tetrasomy of same chromosome, triplication or quadruplication, as well as isoderivative chromosomes, are counted as 2 abnormalities.

  • Constitutional abnormalities are not counted.

  • In case of multiple clones (subclones or independent clones), chromosome abnormalities in each clone/subclone are counted separately and the number of chromosomal abnormalities is defined by the clone with the highest abnormalities.

  • For composite karyotypes, clonal chromosomal aberrations are counted in metaphases with the highest number of abnormalities.

We consider the following when counting abnormalities:

  • Recurrent SVs

  • One CNV ≥ 5 Mbp per chromosome arm

Monosomal Karyotype

According to ELN: Presence of two or more distinct monosomies (excluding loss of X or Y), or one single autosomal monosomy in combination with at least one structural chromosome abnormality (excluding core-binding factor AML).

Last updated

Was this helpful?